Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Merck reported Phase 3 CORALreef Lipids results showing a 55.8% placebo-adjusted LDL-C reduction at week 24 in the primary analysis. A post hoc reanalysis addressing biologically implausible baseline values estimated 59.7%. LDL-C reductions persisted through week 52. These lipid findings should not be equated with demonstrated reductions in cardiovascular events.
Continue your research
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
